IL2 and neoplasm: A significant regression of tumor growth was exerted by an anti‐PD‐1 antibody treatment in the CT26‐bearing mice receiving FPC2‐IG‐IL‐2 compared to those receiving PBS or FPC2‐IG (Figure 4f).